Literature DB >> 31532246

Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells.

Ying Fu1, Juan Cai1, Fanghua Li1, Zhiwen Liu1, Shaoqun Shu1, Ying Wang1, Yuxue Liu1, Chengyuan Tang1, Zheng Dong2.   

Abstract

Cisplatin is a commonly used chemotherapeutic drug for cancer treatment, but its nephrotoxicity may lead to the deterioration of renal function. Previous work has been focused on cisplatin-induced acute kidney disease, whereas the mechanism of chronic kidney disease after cisplatin chemotherapy is largely unknown. In the present study, we have characterized the mouse model of chronic kidney defects induced by repeated low-dose cisplatin treatment. We have also established a relevant cell culture model. In the animal model, C57 mice were given weekly injection of 8 mg/kg cisplatin for 4 wk. This led to a sustained decline of kidney function. These mice showed loss of kidney mass, interstitial fibrosis, continued activation of inflammatory cytokines, and appearance of atubular glomeruli. In the cell model, the BUMPT mouse proximal tubular cell line was treated four times with 1-2 μM cisplatin, resulting in low levels of apoptosis and the expression of fibrosis proteins and profibrotic factors. These data suggest that repeated treatment with low-dose cisplatin causes long-term renal pathologies with characteristics of chronic kidney disease.

Entities:  

Keywords:  chronic kidney disease; cisplatin; fibrosis; kidney repair; nephrotoxicity

Mesh:

Substances:

Year:  2019        PMID: 31532246     DOI: 10.1152/ajprenal.00385.2019

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  16 in total

1.  Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury.

Authors:  Dengpiao Xie; Gaizun Hu; Chaoling Chen; Fereshteh Ahmadinejad; Weili Wang; Pin-Lan Li; David A Gewirtz; Ningjun Li
Journal:  Am J Physiol Renal Physiol       Date:  2022-07-14

2.  Endoplasmic reticulum stress contributes to cisplatin-induced chronic kidney disease via the PERK-PKCδ pathway.

Authors:  Shaoqun Shu; Hui Wang; Jiefu Zhu; Ying Fu; Juan Cai; Anqun Chen; Chengyuan Tang; Zheng Dong
Journal:  Cell Mol Life Sci       Date:  2022-07-27       Impact factor: 9.207

Review 3.  Cisplatin nephrotoxicity: new insights and therapeutic implications.

Authors:  Chengyuan Tang; Man J Livingston; Robert Safirstein; Zheng Dong
Journal:  Nat Rev Nephrol       Date:  2022-10-13       Impact factor: 42.439

4.  C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury.

Authors:  Sophia M Sears; Cierra N Sharp; Austin Krueger; Gabrielle B Oropilla; Douglas Saforo; Mark A Doll; Judit Megyesi; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-24

5.  Evaluation of cisplatin-induced injury in human kidney organoids.

Authors:  Jenny L M Digby; Thitinee Vanichapol; Aneta Przepiorski; Alan J Davidson; Veronika Sander
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-09

6.  PARK7 Protects Against Chronic Kidney Injury and Renal Fibrosis by Inducing SOD2 to Reduce Oxidative Stress.

Authors:  Lijun Yin; Honglin Li; Zhiwen Liu; Wenwen Wu; Juan Cai; Chengyuan Tang; Zheng Dong
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

7.  Porcine models of acute kidney injury.

Authors:  Jianni Huang; George Bayliss; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2021-04-26

Review 8.  COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.

Authors:  Cathleen Lutz; Leigh Maher; Charles Lee; Wonyoung Kang
Journal:  Hum Genomics       Date:  2020-06-04       Impact factor: 4.639

9.  Regulated cell death in cisplatin-induced AKI: relevance of myo-inositol metabolism.

Authors:  Fei Deng; Xiaoping Zheng; Isha Sharma; Yingbo Dai; Yinhuai Wang; Yashpal S Kanwar
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-22

10.  Potential Therapeutic Targets for Cisplatin-Induced Kidney Injury: Lessons from Other Models of AKI and Fibrosis.

Authors:  Sophia Sears; Leah Siskind
Journal:  J Am Soc Nephrol       Date:  2021-05-28       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.